{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:06:53Z","timestamp":1792206413218,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jtha.2022.10.016","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T10:24:05Z","timestamp":1674642245000},"page":"269-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment with recombinant ADAMTS13, alleviates hypoxia\/reoxygenation-induced pathologies in a mouse model of human sickle cell disease"],"prefix":"10.1016","volume":"21","author":[{"given":"Paolo","family":"Rossato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Glantschnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Canneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sogue","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Schrenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Voelkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dockal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Plaimauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanspeter","family":"Rottensteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Gritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Federti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Matte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"De Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Scheiflinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Hoellriegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2022.10.016_bib1","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","article-title":"Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies","volume":"122","author":"Manwani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.016_bib2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-0031-1273087","article-title":"Thrombosis and sickle cell disease","volume":"37","author":"De Franceschi","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2022.10.016_bib3","doi-asserted-by":"crossref","first-page":"985210","DOI":"10.1155\/2013\/985210","article-title":"Oxidative stress and \u03b2-thalassemic erythroid cells behind the molecular defect","volume":"2013","author":"De Franceschi","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jtha.2022.10.016_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.blre.2015.12.003","article-title":"Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies","volume":"30","author":"Noubouossie","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2022.10.016_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/CH-189013","article-title":"Hypercoagulable state in sickle cell disease","volume":"68","author":"Faes","year":"2018","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.jtha.2022.10.016_bib6","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood.2019000424","article-title":"Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease","volume":"133","author":"Faes","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.016_bib7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/jth.13696","article-title":"von Willebrand factor and inflammation","volume":"15","author":"Kawecki","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.016_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5620314","article-title":"The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy","volume":"2017","author":"Gragnano","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jtha.2022.10.016_bib9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1160\/TH14-09-0731","article-title":"VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP","volume":"113","author":"Schwameis","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.016_bib10","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.016_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/918916","article-title":"Role of extracellular hemoglobin in thrombosis and vascular occlusion in patients with sickle cell anemia","volume":"2011","author":"Zhou","year":"2011","journal-title":"Anemia"},{"key":"10.1016\/j.jtha.2022.10.016_bib12","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1160\/TH08-10-0677","article-title":"Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease","volume":"101","author":"Zhou","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.016_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.20653","article-title":"ADAMTS13 activity in sickle cell disease","volume":"81","author":"Schnog","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2022.10.016_bib14","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1182\/blood-2010-08-302539","article-title":"The rate\u00a0of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma","volume":"117","author":"Chen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.016_bib15","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.3324\/haematol.2021.280233","article-title":"Evidence of protective effects of recombinant ADAMTS13 in humanized model for sickle cell disease","volume":"107","author":"Rossato","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.10.016_bib16","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3324\/haematol.2015.124586","article-title":"Dietary \u03c9-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease","volume":"100","author":"Kalish","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.10.016_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00235398","article-title":"Ca(2+)-activated K+ channels of human and rabbit erythrocytes display distinctive patterns of inhibition by venom peptide toxins","volume":"147","author":"Brugnara","year":"1995","journal-title":"J Membr Biol"},{"key":"10.1016\/j.jtha.2022.10.016_bib18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1126\/science.278.5339.873","article-title":"Knockout-transgenic mouse model of sickle cell disease","volume":"278","author":"Ryan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jtha.2022.10.016_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s003359900551","article-title":"Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment","volume":"8","author":"Rogers","year":"1997","journal-title":"Mamm Genome"},{"key":"10.1016\/j.jtha.2022.10.016_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.10.016_bib21","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/j.1537-2995.2010.03020.x","article-title":"A\u00a0shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura","volume":"51","author":"Han","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2022.10.016_bib22","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jth.13341","article-title":"Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura","volume":"14","author":"Kopi\u0107","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.10.016_bib23","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use","volume":"125","author":"Telen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.10.016_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MBC.0000000000001064","article-title":"Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey","volume":"33","author":"Rossato","year":"2022","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622071859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622071859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:35:33Z","timestamp":1761536133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622071859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1538783622071859"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2022.10.016","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with recombinant ADAMTS13, alleviates hypoxia\/reoxygenation-induced pathologies in a mouse model of human sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2022.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}